세계의 동물용 mRNA 백신 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)
mRNA Vaccines for Animals - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
상품코드:1862445
리서치사:QYResearch
발행일:2025년 10월
페이지 정보:영문
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
동물용 mRNA 백신 시장 규모는 2024년에 8,102만 달러로 평가되었고, 2025-2031년의 예측 기간 중 CAGR 61.1%로 확대되어 2031년까지 25억 1,300만 달러에 이를 것으로 예측됩니다.
동물용 mRNA 백신은 메신저 RNA(mRNA) 기술을 이용하여 가축, 반려동물 및 기타 동물의 특정 병원체에 대한 면역반응을 자극하는 수의학 백신의 일종입니다. 이 백신은 바이러스 또는 세균 항원을 암호화하는 합성 mRNA를 동물의 세포에 도입하여 면역 체계가 표적 질병을 인식하고 싸우도록 유도하는 방식으로 작동합니다. 기존 백신에 비해 mRNA 백신은 개발 기간 단축, 효능 향상, 신흥 동물 질병에 대한 신속한 적응이 가능하다는 특징이 있습니다. 가축질병(구제역 등), 인수공통전염병, 반려동물 건강관리 등 다양한 응용 분야에서의 활용이 검토되고 있습니다.
시장 개척 기회와 주요 촉진요인
동물용 mRNA 백신은 차세대 생물학적 제제로서 빠른 개발, 높은 특이성, 확장성으로 인해 전 세계 수의학 백신 상황을 재구성하고 있습니다. 동물 건강 관련 기업의 연례 보고서와 증권사 조사에 따르면, 축산업의 방역 수요, 특히 국경 간 전염병 및 주요 동물 전염병에 대한 수요가 지속적으로 증가하고 있으며, 이는 새로운 백신에 대한 투자를 가속화하고 있습니다. 인체용 코로나19 백신에서 mRNA 기술의 확실한 성공 사례는 수의학 분야에서의 적용 가능성을 뒷받침하고 있습니다. 또한 식품 안전, 축산업 현대화, 공중보건에 대한 강력한 정책적 지원과 함께 동물용 mRNA 백신 시장 확대 가능성은 매우 크다고 할 수 있습니다.
시장 과제, 위험 및 제약 조건
유망한 전망에도 불구하고, 동물용 mRNA 백신은 여러 가지 문제에 직면해 있습니다. 보관, 운송, 대량 생산에는 엄격한 콜드체인과 고도의 설비가 필요하며, 기존 백신에 비해 비용이 많이 듭니다. 규제 프레임워크가 미성숙하고 지역별로 등록 기준과 안전성 검증 기준이 달라 상업화에 불확실성이 존재하고 있습니다. 또한, 이 산업은 기술적, 재정적 우위를 가진 다국적 동물 건강 대기업이 지배하고 있으며, 치열한 경쟁과 잠재적 기술 장벽에 직면한 중소기업의 진입 장벽이 되고 있습니다.
다운스트림 수요 동향
축산업이 대규모화, 집약화되고 소비자의 식품 안전과 동물 위생에 대한 인식이 높아짐에 따라 안전하고 효과적인 신규 백신에 대한 수요는 지속적으로 증가하고 있습니다. 특히 가금류, 돼지, 반려동물 분야에서는 신종 질병에 대한 신속 대응형 백신에 대한 강한 수요를 보이고 있습니다. 정부의 동물 질병 예방에 대한 투자 확대와 농가의 손실 감소 및 효율화 요구가 더 많은 보급을 촉진할 것입니다. 장기적으로 동물용 mRNA 백신은 축산의 안정과 식량 공급의 안전을 뒷받침하는 중요한 기술이 될 전망입니다.
이 보고서는 동물용 mRNA 백신 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고 지역/국가, 유형 및 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
동물용 mRNA 백신 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 과거 데이터와 예측 데이터를 포함하는 매출 수익으로 제시되었습니다. 정량적 분석과 정성적 분석을 통해 독자들이 비즈니스/성장 전략을 수립하고, 시장 경쟁 구도를 평가하고, 현재 시장에서의 자사 위치를 분석하고, 동물용 mRNA 백신에 대한 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
Ceva Animal Health
Merck Animal Health
Areterna
Bayer
BioNTech
Genvax Technologies
BioVenic
Moderna
Ruipu Biotechnology
Jinyu Bio-technology
Shanghai Shen Lian Biomedical
Suzhou Kerui Meide Biomedical Technology
Shanghai Rnacure Biopharma
유형별 부문
비복제형 mRNA 백신
자기 복제형 mRNA 백신
용도별 부문
돼지
가금류
반려동물
반추동물
지역별
북미
미국
캐나다
아시아태평양
중국
일본
한국
동남아시아
인도
호주
기타 아시아태평양
유럽
독일
프랑스
영국
이탈리아
네덜란드
북유럽 국가
기타 유럽
라틴아메리카
멕시코
브라질
기타 라틴아메리카
중동 및 아프리카
튀르키예
사우디아라비아
아랍에미리트(UAE)
기타 중동 및 아프리카
LSH
영문 목차
영문목차
The global market for mRNA Vaccines for Animals was estimated to be worth US$ 81.02 million in 2024 and is forecast to a readjusted size of US$ 2513 million by 2031 with a CAGR of 61.1% during the forecast period 2025-2031.
mRNA vaccines for animals are a type of veterinary vaccine that use messenger RNA (mRNA) technology to stimulate an immune response against specific pathogens in livestock, pets, and other animals. These vaccines work by delivering synthetic mRNA encoding viral or bacterial antigens into the animal's cells, prompting the immune system to recognize and fight the targeted disease. Compared to traditional vaccines, mRNA vaccines offer faster development timelines, improved efficacy, and the ability to rapidly adapt to emerging animal diseases. They are being explored for various applications, including livestock diseases (such as foot-and-mouth disease), zoonotic infections, and companion animal health.
Market Development Opportunities & Main Driving Factors
mRNA vaccines for animals, as a new generation of biological products, are reshaping the global veterinary vaccine landscape with their rapid development, high specificity, and scalability. According to annual reports from animal health companies and brokerage research, the demand for epidemic prevention in the livestock industry continues to rise, particularly against transboundary infectious diseases and major animal epidemics, which accelerates investment in novel vaccines. The proven success of mRNA technology in human COVID-19 vaccines validates its potential in veterinary applications. Coupled with strong policy support for food safety, livestock modernization, and public health, the market expansion potential for animal mRNA vaccines is significant.
Market Challenges, Risks, & Restraints
Despite promising prospects, animal mRNA vaccines face multiple challenges. Their storage, transportation, and mass production require stringent cold chain and advanced equipment, leading to higher costs compared to traditional vaccines. Regulatory frameworks remain immature, with varying standards for registration and safety validation across regions, adding uncertainty to commercialization. Additionally, the industry is dominated by multinational animal health giants with strong technological and financial advantages, creating barriers for smaller firms facing fierce competition and potential technological hurdles.
Downstream Demand Trends
As livestock farming becomes increasingly large-scale and intensive, and as consumer awareness of food safety and animal health grows, demand for safe and effective novel vaccines continues to rise. In particular, poultry, swine, and companion animal sectors exhibit strong demand for rapid-response vaccines against emerging diseases. Growing government investment in animal disease prevention and farmers' need to reduce losses and improve efficiency will further drive adoption. In the long term, animal mRNA vaccines are poised to become a critical technology supporting livestock stability and food supply security.
This report aims to provide a comprehensive presentation of the global market for mRNA Vaccines for Animals, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of mRNA Vaccines for Animals by region & country, by Type, and by Application.
The mRNA Vaccines for Animals market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding mRNA Vaccines for Animals.
Market Segmentation
By Company
Ceva Animal Health
Merck Animal Health
Areterna
Bayer
BioNTech
Genvax Technologies
BioVenic
Moderna
Ruipu Biotechnology
Jinyu Bio-technology
Shanghai Shen Lian Biomedical
Suzhou Kerui Meide Biomedical Technology
Shanghai Rnacure Biopharma
Segment by Type
Non-replicating mRNA vaccines
Self-replicating mRNA vaccines
Segment by Application
Pigs
Poultry
Companion Animals
Ruminants
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of mRNA Vaccines for Animals company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of mRNA Vaccines for Animals in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of mRNA Vaccines for Animals in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
1.1 mRNA Vaccines for Animals Product Introduction
1.2 Global mRNA Vaccines for Animals Market Size Forecast (2020-2031)
1.3 mRNA Vaccines for Animals Market Trends & Drivers
1.3.1 mRNA Vaccines for Animals Industry Trends
1.3.2 mRNA Vaccines for Animals Market Drivers & Opportunity
1.3.3 mRNA Vaccines for Animals Market Challenges
1.3.4 mRNA Vaccines for Animals Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global mRNA Vaccines for Animals Players Revenue Ranking (2024)
2.2 Global mRNA Vaccines for Animals Revenue by Company (2020-2025)
2.3 Key Companies mRNA Vaccines for Animals Manufacturing Base Distribution and Headquarters
2.4 Key Companies mRNA Vaccines for Animals Product Offered
2.5 Key Companies Time to Begin Mass Production of mRNA Vaccines for Animals
2.6 mRNA Vaccines for Animals Market Competitive Analysis
2.6.1 mRNA Vaccines for Animals Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by mRNA Vaccines for Animals Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in mRNA Vaccines for Animals as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Non-replicating mRNA vaccines
3.1.2 Self-replicating mRNA vaccines
3.2 Global mRNA Vaccines for Animals Sales Value by Type
3.2.1 Global mRNA Vaccines for Animals Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global mRNA Vaccines for Animals Sales Value, by Type (2020-2031)
3.2.3 Global mRNA Vaccines for Animals Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Pigs
4.1.2 Poultry
4.1.3 Companion Animals
4.1.4 Ruminants
4.2 Global mRNA Vaccines for Animals Sales Value by Application
4.2.1 Global mRNA Vaccines for Animals Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global mRNA Vaccines for Animals Sales Value, by Application (2020-2031)
4.2.3 Global mRNA Vaccines for Animals Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global mRNA Vaccines for Animals Sales Value by Region
5.1.1 Global mRNA Vaccines for Animals Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global mRNA Vaccines for Animals Sales Value by Region (2020-2025)
5.1.3 Global mRNA Vaccines for Animals Sales Value by Region (2026-2031)
5.1.4 Global mRNA Vaccines for Animals Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America mRNA Vaccines for Animals Sales Value, 2020-2031
5.2.2 North America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
5.3.2 Europe mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific mRNA Vaccines for Animals Sales Value, 2020-2031
5.4.2 Asia Pacific mRNA Vaccines for Animals Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America mRNA Vaccines for Animals Sales Value, 2020-2031
5.5.2 South America mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa mRNA Vaccines for Animals Sales Value, 2020-2031
5.6.2 Middle East & Africa mRNA Vaccines for Animals Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions mRNA Vaccines for Animals Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions mRNA Vaccines for Animals Sales Value, 2020-2031
6.3 United States
6.3.1 United States mRNA Vaccines for Animals Sales Value, 2020-2031
6.3.2 United States mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.3.3 United States mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe mRNA Vaccines for Animals Sales Value, 2020-2031
6.4.2 Europe mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China mRNA Vaccines for Animals Sales Value, 2020-2031
6.5.2 China mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.5.3 China mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan mRNA Vaccines for Animals Sales Value, 2020-2031
6.6.2 Japan mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea mRNA Vaccines for Animals Sales Value, 2020-2031
6.7.2 South Korea mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia mRNA Vaccines for Animals Sales Value, 2020-2031
6.8.2 Southeast Asia mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India mRNA Vaccines for Animals Sales Value, 2020-2031
6.9.2 India mRNA Vaccines for Animals Sales Value by Type (%), 2024 VS 2031
6.9.3 India mRNA Vaccines for Animals Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Ceva Animal Health
7.1.1 Ceva Animal Health Profile
7.1.2 Ceva Animal Health Main Business
7.1.3 Ceva Animal Health mRNA Vaccines for Animals Products, Services and Solutions
7.1.4 Ceva Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.1.5 Ceva Animal Health Recent Developments
7.2 Merck Animal Health
7.2.1 Merck Animal Health Profile
7.2.2 Merck Animal Health Main Business
7.2.3 Merck Animal Health mRNA Vaccines for Animals Products, Services and Solutions
7.2.4 Merck Animal Health mRNA Vaccines for Animals Revenue (US$ Million) & (2020-2025)
7.2.5 Merck Animal Health Recent Developments
7.3 Areterna
7.3.1 Areterna Profile
7.3.2 Areterna Main Business
7.3.3 Areterna mRNA Vaccines for Animals Products, Services and Solutions
